

Article title: Mitigation and Management of Common Toxicities Associated with the Administration of CAR-T Therapies in Oncology Patients

Journal name: *Drug Safety*

Authorship: Jonathan Renninger,^{1†} Lisa Kurz,² Heather Stein³

†Corresponding author:

Jonathan Renninger

GSK Safety Evaluation and Risk Management, Global Safety, Philadelphia, PA, USA

Jon.P.Renninger@gsk.com

Electronic Supplementary Material 1

List of articles reporting incidence of toxicities following chimeric antigen receptor T-cell (CAR-T) therapies

The following references were used to assess incidences of: **cytokine release syndrome** [1-92], **immune effector cell-associated neurotoxicity syndrome** [1-13, 15-19, 22-26, 28, 30-32, 36, 37, 39-42, 44, 45, 50, 51, 53, 55, 56, 58, 60-63, 65, 66, 69-71, 73-84, 86-97], **cytopenias** [1, 5, 7, 15, 20, 24, 27, 29, 30, 32, 35, 36, 40, 47-50, 53, 84-86, 88-91, 93, 95, 98-105], and **infections** [7, 15, 20, 24, 26, 32, 53, 69, 71, 77, 80, 83-87, 89, 95, 99, 104-108].

Supplementary references

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *N Engl J Med*. 2017;377:2531-44. doi:10.1056/NEJMoa1707447
2. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *N Engl J Med*. 2018;378:439-48. doi:10.1056/NEJMoa1709866
3. Qi Y, Zhao M, Hu Y, Wang Y, Li P, Cao J, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. *Blood*. 2022;139:3376-86. doi:10.1182/blood.2021013733

4. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol.* 2019;20:31-42. doi:10.1016/s1470-2045(18)30864-7
5. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 2019;380:45-56. doi:10.1056/NEJMoa1804980
6. Abramson JS, Gordon LI, Palomba ML, Lunning MA, Arnason JE, Forero-Torres A, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. *Journal of Clinical Oncology.* 2018;36:7505-. doi:10.1200/JCO.2018.36.15_suppl.7505
7. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *Blood.* 2017;130:577. doi:https://doi.org/10.1182/blood.V130.Suppl_1.577.577
8. Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *N Engl J Med.* 2017;377:2545-54. doi:10.1056/NEJMoa1708566
9. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. *N Engl J Med.* 2014;371:1507-17. doi:10.1056/NEJMoa1407222
10. Ghorashian S, Kramer AM, Albon SJ, Wright G, Castro F, Popova B, et al. A Novel Low Affinity CD19CAR Results in Durable Disease Remissions and Prolonged CAR T Cell Persistence without Severe CRS or Neurotoxicity in Patients with Paediatric ALL. *Blood.* 2017;130:806. doi:https://doi.org/10.1182/blood.V130.Suppl_1.806.806
11. Qasim W, Ciocarlie O, Adams S, Inglott S, Murphy C, Rivat C, et al. Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product in a First-in-Human Trial (PALL) in Pediatric Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. *Blood.* 2017;130:1271. doi:https://doi.org/10.1182/blood.V130.Suppl_1.1271.1271
12. Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. *Cancer Discov.* 2017;7:1404-19. doi:10.1158/2159-8290.Cd-17-0698

13. DeAngelo DJ. P217 Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study). 32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One. Journal for ImmunoTherapy of Cancer. 2017;5:86. doi:10.1186/s40425-017-0289-3
14. Cohen AD, Garfall AL, Stadtmauer EA, Lacey SF, Lancaster E, Vogl DT, et al. Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM). Blood. 2017;130:505. doi: 10.1182/blood.V130.Suppl_1.505.505
15. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675-84. doi: 10.1182/blood.2022018730
16. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380:1726-37. doi:10.1056/NEJMoa1817226
17. Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, et al. Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. Cancer Med. 2021;10:999-1011. doi:10.1002/cam4.3686
18. Shah BD, Bishop MR, Oluwale OO, Logan AC, Baer MR, Donnellan WB, et al. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood. 2021;138:11-22. doi:10.1182/blood.2020009098
19. Yang Q, Li X, Zhang F, Yang Q, Zhou W, Liu J. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Int J Med Sci. 2021;18:1786-97. doi:10.7150/ijms.46811
20. Qu X, An G, Sui W, Wang T, Zhang X, Yang J, et al. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. J Immunother Cancer. 2022;10. doi:10.1136/jitc-2022-005145

21. Shi X, Yan L, Shang J, Kang L, Yan Z, Jin S, et al. Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma. *Am J Hematol*. 2022;97:537-47. doi:10.1002/ajh.26486
22. Liu Y, Deng B, Hu B, Zhang W, Zhu Q, Liu Y, et al. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma. *Blood Adv*. 2022;6:717-30. doi:10.1182/bloodadvances.2021004557
23. Shalabi H, Qin H, Su A, Yates B, Wolters PL, Steinberg SM, et al. CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR. *Blood*. 2022;140:451-63. doi:10.1182/blood.2022015795
24. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med*. 2022;28:735-42. doi:10.1038/s41591-022-01731-4
25. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *J Clin Oncol*. 2020;38:415-22. doi:10.1200/jco.19.01892
26. Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. *J Hematol Oncol*. 2023;16:34. doi:10.1186/s13045-023-01427-3
27. Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. *Proc Natl Acad Sci U S A*. 2019;116:9543-51. doi:10.1073/pnas.1819745116
28. Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. *Br J Haematol*. 2021;194:690-700. doi:10.1111/bjh.17527
29. Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. *J Hematol Oncol*. 2022;15:88. doi:10.1186/s13045-022-01308-1

30. Sesques P, Ferrant E, Safar V, Wallet F, Tordo J, Dhompas A, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. *Am J Hematol*. 2020;95:1324-33. doi:10.1002/ajh.25951
31. Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *J Clin Invest*. 2019;129:2210-21. doi:10.1172/jci126397
32. Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. *Transplant Cell Ther*. 2022;28:581.e1-.e8. doi:10.1016/j.jtct.2022.05.026
33. Sang W, Wang X, Geng H, Li T, Li D, Zhang B, et al. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma. *Front Immunol*. 2022;13:858021. doi:10.3389/fimmu.2022.858021
34. Shao M, Yu Q, Teng X, Guo X, Wei G, Xu H, et al. CRS-related coagulopathy in BCMA targeted CAR-T therapy: a retrospective analysis in a phase I/II clinical trial. *Bone Marrow Transplant*. 2021;56:1642-50. doi:10.1038/s41409-021-01226-9
35. Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies. *Mol Ther*. 2021;29:636-44. doi:10.1016/j.ymthe.2020.09.027
36. Wei J, Xiao M, Mao Z, Wang N, Cao Y, Xiao Y, et al. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT. *Signal Transduct Target Ther*. 2022;7:101. doi:10.1038/s41392-022-00924-0
37. An L, Lin Y, Deng B, Yin Z, Zhao D, Ling Z, et al. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. *BMC Cancer*. 2022;22:393. doi:10.1186/s12885-022-09489-1
38. Zhao Y, Zhang J, Yang J, Wu H, Chen Y, Li N, et al. Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy. *Front Oncol*. 2022;12:884782. doi:10.3389/fonc.2022.884782

39. Huang L, Li J, Yang J, Zhang X, Zhang M, He J, et al. Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma. *Cells*. 2022;11. doi:10.3390/cells11244085
40. Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z, et al. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas. *Transplantation and Cellular Therapy*. 2021;27:910.e1-.e11. doi: 10.1016/j.jtct.2021.08.012
41. Wu J, Meng F, Cao Y, Zhang Y, Zhu X, Wang N, et al. Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. *Blood Cancer J*. 2021;11:131. doi:10.1038/s41408-021-00523-2
42. Wang X, Qi Y, Li H, Liu F, Cao J, Chen W, et al. Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy. *Front Immunol*. 2022;13:943004. doi:10.3389/fimmu.2022.943004
43. Mao Y, Xu X. Cytokine Release Syndrome after Treatment of Anti-CD19 CAR-T Therapy with IL-6 Knocking Down in Patients with Central Nervous System B-cell Acute Lymphocytic Leukemia. *Ann Clin Lab Sci*. 2021;51:790-4.
44. Zhang Q, Zu C, Jing R, Feng Y, Zhang Y, Zhang M, et al. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. *Front Immunol*. 2023;14:1125357. doi:10.3389/fimmu.2023.1125357
45. Grover P, Veilleux O, Tian L, Sun R, Previtera M, Curran E, et al. Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia. *Blood Adv*. 2022;6:1608-18. doi:10.1182/bloodadvances.2020003482
46. Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R, et al. Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. *Clin Cancer Res*. 2021;27:6384-92. doi:10.1158/1078-0432.Ccr-21-2031
47. Lu W, Wei Y, Cao Y, Xiao X, Li Q, Lyu H, et al. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. *Cancer Immunol Immunother*. 2021;70:3501-11. doi:10.1007/s00262-021-02941-4

48. Zhang Y, Wang Y, Liu Y, Tong C, Wang C, Guo Y, et al. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial. *Leukemia*. 2022;36:189-96. doi:10.1038/s41375-021-01345-8
49. Yan L, Qu S, Shang J, Shi X, Kang L, Xu N, et al. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma. *Cancer Med*. 2021;10:563-74. doi:10.1002/cam4.3624
50. Makita S, Yamamoto G, Maruyama D, Asano-Mori Y, Kaji D, Ananthakrishnan R, et al. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Cancer Med*. 2022;11:4889-99. doi:10.1002/cam4.4820
51. Stolz S, Roncador M, Rösler W, Zenz T, Manz MG, Müller AMS, et al. Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. *Swiss Med Wkly*. 2022;152:w30186. doi:10.4414/smw.2022.w30186
52. Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2019;25:1092-8. doi:10.1016/j.bbmt.2019.02.008
53. Zhou X, Tu S, Wang C, Huang R, Deng L, Song C, et al. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas. *Front Immunol*. 2020;11:564099. doi:10.3389/fimmu.2020.564099
54. Guha A, Addison D, Jain P, Gutierrez JM, Ghosh A, Roddie C, et al. Cardiovascular Events Associated with Chimeric Antigen Receptor T Cell Therapy: Cross-Sectional FDA Adverse Events Reporting System Analysis. *Biol Blood Marrow Transplant*. 2020;26:2211-6. doi:10.1016/j.bbmt.2020.08.036
55. Heng G, Jia J, Li S, Fu G, Wang M, Qin D, et al. Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia. *Clin Cancer Res*. 2020;26:1606-15. doi:10.1158/1078-0432.Ccr-19-1339
56. Ma F, Ho JY, Du H, Xuan F, Wu X, Wang Q, et al. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. *Hematol Oncol*. 2019;37:601-8. doi:10.1002/hon.2672

57. Ying Z, Xie Y, Zheng W, Liu W, Lin N, Tu M, et al. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial. *Bone Marrow Transplant.* 2023;58:288-94. doi:10.1038/s41409-022-01888-z
58. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet.* 2021;398:314-24. doi:10.1016/s0140-6736(21)00933-8
59. Hu Y, Zhou Y, Zhang M, Ge W, Li Y, Yang L, et al. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. *Clin Cancer Res.* 2021;27:2764-72. doi:10.1158/1078-0432.Ccr-20-3863
60. Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nat Med.* 2022;28:2145-54. doi:10.1038/s41591-022-01969-y
61. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med.* 2022;28:325-32. doi:10.1038/s41591-021-01622-0
62. Roddie C, Dias J, O'Reilly MA, Abbasian M, Cadinanos-Garai A, Vispute K, et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. *J Clin Oncol.* 2021;39:3352-63. doi:10.1200/jco.21.00917
63. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. *J Clin Oncol.* 2021;39:3340-51. doi:10.1200/jco.21.00389
64. Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk N, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. *Blood.* 2023;141:219-30. doi:10.1182/blood.2022015526
65. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. *J Clin Oncol.* 2020;38:3119-28. doi:10.1200/jco.19.02104

66. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouse R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Blood Adv.* 2020;4:5414-24. doi:10.1182/bloodadvances.2020003092
67. Larson SM, Walthers CM, Ji B, Ghafouri SN, Naparstek J, Trent J, et al. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. *Cancer Discov.* 2023;13:580-97. doi:10.1158/2159-8290.Cd-22-0964
68. Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L, et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. *Blood Cancer J.* 2023;13:61. doi:10.1038/s41408-023-00822-w
69. Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. *J Clin Oncol.* 2022;40:2246-56. doi:10.1200/jco.21.01676
70. Xia J, Li H, Yan Z, Zhou D, Wang Y, Qi Y, et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial. *J Clin Oncol.* 2023;41:2583-93. doi:10.1200/jco.22.01824
71. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, et al. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. *J Clin Oncol.* 2022;40:945-55. doi:10.1200/jco.20.03585
72. Chen LY, Gong WJ, Li MH, Zhou HX, Xu MZ, Qian CS, et al. Anti-CD19 CAR T-cell consolidation therapy combined with CD19⁺ feeding T cells and TKI for Ph⁺ acute lymphoblastic leukemia. *Blood Adv.* 2023;7:4913-25. doi:10.1182/bloodadvances.2022009072
73. Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W, et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. *J Immunother Cancer.* 2023;11. doi:10.1136/jitc-2022-005701
74. Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. *Blood.* 2019;134:636-40. doi:10.1182/blood.2019000905

75. Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, et al. Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. *Lancet Oncol.* 2023;24:913-24. doi:10.1016/s1470-2045(23)00222-x
76. Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, et al. CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies. *Front Immunol.* 2022;13:1074740. doi:10.3389/fimmu.2022.1074740
77. Ri M, Suzuki K, Ishida T, Kuroda J, Tsukamoto T, Teshima T, et al. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort. *Cancer Sci.* 2022;113:4267-76. doi:10.1111/cas.15556
78. Jacoby E, Bielezai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. *Am J Hematol.* 2018;93:1485-92. doi:10.1002/ajh.25274
79. Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. *J Clin Oncol.* 2017;35:3010-20. doi:10.1200/jco.2017.72.8519
80. Minakata D, Ishida T, Ando K, Suzuki R, Tanaka J, Hagiwara S, et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. *Int J Hematol.* 2023;117:729-37. doi:10.1007/s12185-023-03538-6
81. Ying Z, Yang H, Guo Y, Li W, Zou D, Zhou D, et al. Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. *Cytotherapy.* 2023;25:521-9. doi:10.1016/j.jcyt.2022.10.011
82. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, et al. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. *J Clin Oncol.* 2020;38:3095-106. doi:10.1200/jco.19.02103
83. Jacobson CA, Chavez JC, Sehgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. *Lancet Oncol.* 2022;23:91-103. doi:10.1016/s1470-2045(21)00591-x

84. Shah BD, Ghobadi A, Oluwale OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet*. 2021;398:491-502. doi:10.1016/s0140-6736(21)01222-8
85. Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). *J Clin Oncol*. 2023;41:1275-84. doi:10.1200/jco.22.00690
86. Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, et al. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. *Lancet Haematol*. 2022;9:e833-e43. doi:10.1016/s2352-3026(22)00245-9
87. Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, Flynn JR, Devlin SM, et al. Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. *Blood Cancer J*. 2020;10:79. doi:10.1038/s41408-020-00346-7
88. Kong D, Ping N, Gao X, Zou R, Wang P, Wu D, et al. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center. *Front Immunol*. 2023;14:1200748. doi:10.3389/fimmu.2023.1200748
89. Bouchkouj N, Lin X, Wang X, Przepiorka D, Xu Z, Purohit-Sheth T, et al. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. *Oncologist*. 2022;27:892-9. doi:10.1093/oncolo/oyac163
90. Panaite L, Gauthier J, Perkins P, Voutsinas J, Wu QV, Kirk A, et al. Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. *Blood*. 2020;136:1-2. doi:https://doi.org/10.1182/blood-2020-134816
91. Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan WW, et al. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. *Clin Cancer Res*. 2022;28:1759-64. doi:10.1158/1078-0432.Ccr-21-3803

92. Jess J, Yates B, Dulau-Florea A, Parker K, Inglefield J, Lichtenstein D, et al. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. *J Immunother Cancer*. 2023;11. doi:10.1136/jitc-2022-005898
93. Fukuhara N, Kato K, Goto H, Takeshi T, Kawaguchi M, Tokushige K, et al. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. *Int J Hematol*. 2023;117:251-9. doi:10.1007/s12185-022-03481-y
94. Nasta SD, Hughes ME, Namoglu EC, Garfall A, DiFilippo H, Ballard HJ, et al. Outcomes of Tisagenlecleucel in Lymphoma Patients With Predominant Management in an Ambulatory Setting. *Clin Lymphoma Myeloma Leuk*. 2022;22:e730-e7. doi:10.1016/j.clml.2022.04.012
95. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. 2020;382:1331-42. doi:10.1056/NEJMoa1914347
96. Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. *Cancer Discov*. 2018;8:958-71. doi:10.1158/2159-8290.Cd-17-1319
97. Shalabi H, Martin S, Yates B, Wolters PL, Kaplan C, Smith H, et al. Neurotoxicity following CD19/CD28 ζ CAR T-cells in children and young adults with B-cell malignancies. *Neuro Oncol*. 2022;24:1584-97. doi:10.1093/neuonc/noac034
98. Baird JH, Epstein DJ, Tamaresis JS, Ehlinger Z, Spiegel JY, Craig J, et al. Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. *Blood Adv*. 2021;5:143-55. doi:10.1182/bloodadvances.2020002732
99. Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu QV, Voutsinas J, et al. Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. *Biol Blood Marrow Transplant*. 2020;26:26-33. doi:10.1016/j.bbmt.2019.08.003
100. Panaite L, Wu QV, Voutsinas J, Mullane E, Chow VA, Lynch RC, et al. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. *Leukemia & Lymphoma*. 2022;63:2918-22. doi:10.1080/10428194.2022.2095632

101. Xia Y, Zhang J, Li J, Zhang L, Li J, Fan L, et al. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors. *Ann Med*. 2022;54:2951-65. doi:10.1080/07853890.2022.2136748
102. Qiu T, Hu L, Zhang Y, Wang Y, Ma S, Li D, et al. Cytopenia after CAR-T cell therapy: Analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma. *Oncol Lett*. 2023;26:338. doi:10.3892/ol.2023.13924
103. Zhou J, Zhang Y, Shan M, Zong X, Geng H, Li J, et al. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma. *Front Immunol*. 2022;13:997589. doi:10.3389/fimmu.2022.997589
104. Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. *Blood Adv*. 2022;6:6109-19. doi:10.1182/bloodadvances.2022008320
105. Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. *J Hematol Oncol*. 2023;16:88. doi:10.1186/s13045-023-01465-x
106. Mercadal S, Gomez CA, Lee CJ, Couriel DR. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature. *Ann Hematol*. 2023;102:1837-43. doi:10.1007/s00277-023-05131-7
107. Wittmann Dayagi T, Sherman G, Bielorai B, Adam E, Besser MJ, Shimoni A, et al. Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. *Leuk Lymphoma*. 2021;62:1692-701. doi:10.1080/10428194.2021.1881506
108. McGann M, Velayati A, Roubal K, Granger K, Davis JA, Gaffney KJ, et al. Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies. *Leuk Lymphoma*. 2023;64:1592-5. doi:10.1080/10428194.2023.2220455

Electronic Supplementary Material 2

Ongoing clinical trials on the treatment of cytokine release syndrome following CAR-T Therapies (ClinicalTrials.gov^a)

Study title	NCT number
A Phase 2 Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy	NCT04071366
Phase 1B/2A Study of CTO1681 for the Prevention and Treatment of Cytokine Release Syndrome in Patients with Diffuse Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy	NCT05905328
Pilot, Open-Label Study Evaluating the Safety and Feasibility of Using Rescue Therapies for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome	NCT05306080
Effectivity of Extracorporeal Cytokine Adsorption (Cytosorb) as Additive Treatment of CAR-T Cell Associated Cytokine Release (CRS) Syndrome and Encephalopathy Syndrome (CRES)	NCT04048434
A Phase II Study of IL-1 Receptor Antagonist Anakinra to Prevent Severe Neurotoxicity and Cytokine Release Syndrome in Patients Receiving CD19-Specific Chimeric Antigen Receptor (CAR) T Cells	NCT04148430
Metoprolol for the Treatment for Cytokine Release Syndrome in Patients Treated with Chimeric Antigen Receptor T Cells	NCT04082910

Phase I Study of Cytokine Release Syndrome Prophylaxis and Treatment with Siltuximab	NCT05665725
A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Hematological Malignancies	NCT04975555
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity	NCT04150913
^a Search performed on 30 November, 2023	